News | May 21, 2008

First Patients Enrolled in MIV Therapeutics VESTASYNC II Study

May 22, 2008 - MIV Therapeutics Inc. has enrolled the first patients in the registration trial of its VESTAsync polymer-free drug-eluting stent, as the company accelerates its timeline for the VESTASYNC II trial after positive nine-month human safety and efficacy data were reported in March at the American College of Cardiology meeting.

The VESTASYNC II trial is designed to test the efficacy of the VESTAsync in a sufficient number of patients to form the basis of a regulatory filing for marketing approval in Europe. It is anticipated that these patient data will also be part of an eventual submission to the U.S. FDA.

Alexandre Abizaid, M.D., Ph.D., chief of coronary intervention of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, is a principal investigator in this 120-patient, multi-center, randomized, controlled study. In this study 90 patients will receive the VESTAsync nano-porous hydroxyapatite (HAp) coated drug-eluting stent, while 30 patients will receive the company’s VESTAcor stent, the company’s nano-porous HAp coated stent, which contains no drug. The primary endpoint is late lumen loss as measured by quantitative coronary angiography (QCA) at nine months. Secondary endpoints will include major adverse cardiac events and volumetric obstruction. Intravascular ultrasound (IVUS), optical coherent tomography (OCT) and physiological substudies are also expected to be performed.

“We are accelerating this registration trial due to the results obtained with the VESTAsync in our pilot study after nine-month patient follow up, and the potential to address safety issues in currently marketed drug-eluting stents using polymers to deliver drug,” commented Dr. Mark Landy, president and chief executive officer of MIV Therapeutics. “Our stent is a polymer-free, nanoscale, microporous hydroxyapatite stent that has the ability to deliver a much smaller effective dose of drug, in fact 60 percent less, with the safety of bare-metal stents, and probably requires only short-term anticoagulant therapy. Currently available drug-eluting stents require patients to take anticoagulants, such as Plavix, for as long as one year. We intend for the data obtained from this study to support an application for CE mark of the VESTAsync by the end of 2009 and are looking forward eventually to offering patients and physicians a superior alternative to currently available products,” Dr. Landy added.

For more information: www.mivtherapeutics.com

Related Content

Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Overlay Init